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Abstract
Patent foramen ovale is strongly associated with cryptogenic stroke. Various 
clinical trials has shown the association between cryptogenic stroke and 
incidence of undelrying patent foramen ovale, these trials also shown the 
decrease of cryptogenic stroke incidence with the treatment of patent 
foramen ovale Lesion. In the absence of absolute contraindications, patients 
with patent foramen ovale are advised to undergo closure. Preprocedural 
examinations such as trans esophageal echocardiography and pretreatment 
with anticoagulants are required to prevent peri and postprocedural adverse 
events. Currently, patent foramen ovale Closure can be done through a 
percutaneous access with minimal risk. Treatment of patent foramen ovale 
can help decrease future incidences of strokes
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stroke
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Introduction
Patent foramen ovale is being thought to be one of the factors causing cryptogenic stroke and about 40% patient cryptogenic stroke has patent foramen ovale.1 It takes centuries & 
there are numerous lessons to be learned from the patent 
foramen ovale history until an effective treatment. In 
1490, DaVinci first describe communication between 
the atria in pigs and ox. Virchow in 1570, first mentioned 
about physiologic importance of the structure in the 
fetal circulation & the phenomenon of embolization in 
the vascular system. Julius Cohnheim one of Virchow’s 
students, in 1877 described a paradoxical embolism 
through the patent foramen ovale. Starting in the 1900s 
the closure of patent foramen ovale was considered as 
one of the effective therapies. Blakemore in 1939 & 
Murray in 1948 did the first surgical patent foramen 
ovale closures. Finally, in 1992, the first percutaneous 
patent foramen ovale closures were conducted by Lock-
in 36 patients with known right-to-left atrial shunting 
and presumed paradoxical emboli.2,3
Previous Studies on Patent Foramen Ovale 
Closure
Since then a lot of devices have been made & design 
specially for patent foramen ovale closure from many 
factories, but unfortunately, not all of them could 
perform equally well. As an example the STARFlex 
Septal Closure System (NMT Medical Inc., Boston) 
of the CLOSURE I trial, 2012, demonstrated lower 
implantation success and closure rates (89% and 86%, 
respectively) than other patent foramen ovale occlusion 
devices at that time,  on other hand, it also showed 
no significant advantage of patent foramen ovale 
closure makes dampened the enthusiasm tremendously 
for doing this procedure. The Incidence of post-
implantation atrial fibrillation and atrial thrombus 
formation at 6-month rates was relatively high (5.7% 
and 1.1%, respectively) that cause stroke in half of the 
patients who have thrombus.
 Long-term follow-up trials examining the 
effectiveness of devices for the prevention of an event, 
the risk of which is low at baseline and cumulative 
over time was well demonstrated by the RESPECT 
(Randomized Evaluation of Recurrent Stroke 
Comparing patent foramen ovale Closure to Established 
Current Standard of Care) trial which randomized 980 
stroke patients to patent foramen ovale closure versus 
medical management.4 In the short-term analysis (2.6-
year median follow-up), there was a strong trend toward 
a benefit for patent foramen ovale closure but did not 
reach statistical significance (P = 0.08). However, after 
a long-term follow-up of 5.9 years, RESPECT showed 
a more pronounced, now statistically significant stroke 
risk reduction with patent foramen ovale closure 
compared to medical therapy.
Appropriate patient selection is another important 
lesson, these kinds of criteria have been described well 
from several trials, and all of them showing a benefit 
of patent foramen ovale closure compared to medical 
therapy alone. In the RESPECT trial, only patients 
with patent foramen ovale who had objective evidence 
of a stroke by neuroimaging were enrolled.5 CLOSE 
(patent foramen ovale Closure or Anticoagulation 
vs. Antiplatelets after Stroke) trial, including only 
patients with an atrial septal aneurysm or large shunt.6 
DEFENSE-patent foramen ovale (Cryptogenic Stroke 
and High-Risk patent foramen ovale) trials conducted in 
Korea, having only those with a hypermobile interatrial 
septum, atrial septal aneurysm, or a separation of 
the septum primum from secundum of 12 mm as 
an inclusion criterion.7  REDUCE (patent foramen 
ovale Closure or Antiplatelet Therapy for Cryptogenic 
Stroke) trial, exclude patients with evidence for small 
vessel ischemic disease, i.e., prior lacunar infarct(s), 
uncontrolled diabetes mellitus or hypertension, 
autoimmune disease, and alcohol abuse.8
Indications and Contraindications for Patent 
Foramen Ovale Closure
In real-world clinical practice, it is not that simple 
to prove cryptogenic stroke related to patent foramen 
ovale and then to make decisions for patent foramen 
ovale closure. The RoPE score helps us to calculate 
the possibility of cryptogenic stroke caused by patent 
foramen ovale, it is also can be used to predict the risk 
of recurrent stroke and mortality risk after the patent 
foramen ovale closure procedure. RoPE score of ≤ 6 
indicates a high risk of recurrent paradoxical embolism 
and mortality after patent foramen ovale closure.9
Meta-analysis of Randomized Controlled Trials 
(RCT) has shown the benefit of patent foramen ovale 
closure to reduce the risk of recurrent stroke in high-
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risk patient criteria.10 According to a meta-analysis of 
absolute mean reduction in the risk of recurrent stroke 
at patent foramen ovale closure is only 1.0 per 100 
patients per year, however, long-term prevention of 
secondary stroke prevention in young patients should 
be considered.11 In RESPECT, CLOSE dan REDUCE 
trial, participants who enrolled were categorized as a 
young adult below 60 years old with an average of 51.2 
years old in DEFENSE trial.5,6,8,7  Other meta-analyses 
showed that patent foramen ovale closure increases 
the incidence of new-onset atrial fibrillation and atrial 
flutter compared to medical treatment only.12
When patients came with a cryptogenic stroke, 
age under 60 years old & have an indication for patent 
foramen ovale closure, it is recommended to have a 
team who systematically review & make a decision for 
the patent foramen ovale closure procedure as seen in 
picture 1, which consist of multidisciplinary specialist 
doctors.
Patent foramen ovale closure is recommended 
in patients with cryptogenic stroke who have been 
well investigated systematically and have high-risk 
morphology of patent foramen ovale. Patent foramen 
ovale closure is not recommended in pregnant 
cryptogenic stroke patient and one who cannot receive 
antiplatelet treatment after the procedure.
Patent Foramen Ovale Closure Procedure
Percutaneous patent foramen ovale Closure can be 
performed in a standard catheterization laboratory under 
fluoroscopic and Transesophageal Echocardiography 
(TEE) guidance. General anesthesia is almost required 
to facilitate TEE. Adequate anticoagulation using 
unfractionated heparin 80-100 IU/kg body weight, 
administered intravenously. The femoral vein is used 
as a puncture site, crossing the patent foramen ovale 
channel using Multipurpose (MP) Catheter 6F with 
guidewire & directly to the left upper pulmonary vein. 
Patent foramen ovale lesion sizing can be done using 
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Figure 1.  Evidence-Based Algorithm for patent foramen ovale Closure in Ischemic Stroke Patients for Highest 
Clinical Yield, Based on Randomized Trials and Guidelines. (Adapted from Mojadidi et al Cryptogenic Stroke and 
patent foramen ovale. J Am Coll Cardiol 2018;71(9):1035-1043 and Baumgartner et al, 2020 ESC Guidelines for 
the management of adult congenital heart disease. Eur Heart J. 2021;42(6):563-645. ). 13,14
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a balloon with angiographic analysis or by TEE image 
which can obtain information more accurately. A left 
anterior oblique fluoroscopy projection will show a 
good septum profile.  
After sizing the patent foramen ovale, an appropriate 
device including its delivery sheath can be selected. MP 
catheter then can be changed to the selected delivery 
sheath. To minimize the risk of air emboli, during this 
step de-bubble and flushing the catheter is crucial. 
The left atrial disc is deployed gradually start from 
the upper left pulmonary artery while keeps pulling 
back to patent foramen ovale and then deploy the 
right disc. Confirmation of adequate position using 
echocardiography and fluoroscopy should be performed 
once the device is placed before its final release.
 Antibiotic regimen after the procedure is based on 
local hospital policy.12 Antithrombotic therapy with 
dual antiplatelet (DAPT) are given for 6 months after 
the procedure then after that single antiplatelet therapy 
could continue for 5 years depending on clinical features 
of the patient including recurrent thromboembolic & 
bleeding risk.
Transthoracic Echocardiography (TTE) evaluation 
is done before patient discharge and the sixth week to 
exclude pericardial effusion and device embolization. 
Routine TEE performed If only there is a significant 
residual patent foramen ovale leakage or recurrent 
clinical stroke & c-TCD is performed on the sixth 
month after. c-TCD evaluation is carried out every 
year for 5 years. Complete closure is varying from each 
patient's endothelialization of the device and can take 
up to sixth months.
The complication rate is about 1 in 14 patients 
undergoing transcutaneous patent foramen ovale closure, 
especially in older ages.15 Major adverse events could 
happen related to the procedure, including death, stroke, 
air emboli, device embolization, vascular complication, 
bleeding complication, Atrial Fibrillation (transient or 
sustained), myocardial infarction, pericardial effusion 
with or without tamponade. Some postprocedural 
major adverse events are stroke, deep vein thrombosis or 
pulmonary embolism if occurring within 6 months after 
the procedure, atrial fibrillation, atrial flutter, ventricular 
tachyarrhythmias, or complete heart block requiring 
pharmacologic therapy or cardioversion, Thrombus on 
the device detected, pericardial effusion, device erosion, 
device explantation.16
Requirements for Patent Foramen Ovale 
Closure
There are several requirements for operators and 
institutions who are allowed to performed transcutaneous 
patent foramen ovale Closure. These requirements 
are taken from the SCAI expert consensus statement 
on the operator and institutional requirements for 
patent foramen ovale closure for secondary prevention 
of paradoxical embolic stroke 2019 and have been 
modified.16
Operator Requirements 
1. Should have comprehensive knowledge of atrial/ 
patent foramen ovale anatomy dan imaging 
2. Have experience at least 50 cases of structural 
intervention with either minimum of 25 cases 
involving septal intervention or 12 cases of patent 
foramen ovale intervention procedures under 
proctor or mentor. 
3. Experience with catheter-based management 
of potential complications, including 
pericardiocentesis, recognition of device 
malposition, and embolized device retrieval
Institution Requirements 
1. Have experience at least 75 cases of structural 
intervention in the last 5 years.
2. Done at least 25 cases of structural intervention per 
year with a minimum of 10 cases involving septal 
intervention.
3. Have a multidisciplinary team that includes 
necessary staff and expertise for perioperative 
evaluation, performing the patent foramen ovale 
closure procedure, and acute and long-term 
postprocedural follow-up
4. Have catheterization laboratories that have been 
standardized by the Indonesian government 
authority.
5. Have good access to the cardiothoracic surgery 
theater to overcome the adverse event that might be 
happening.
6. Strongly recommended to have a patent foramen 
ovale Closure registry.
Before the patent foramen ovale closure procedure, 
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it must be ensured that the patient and his family 
received information about periprocedural preparation, 
the intraprocedural process including the risk of adverse 
events, and postprocedural treatment. Education for 
the patient is also mandatory to increase the patient’s 
awareness and adherence to long-term medication and 
treatment.
Conclusion
Closure of patent foramen ovale lesion should 
be done in all clinically eligible patients to improve 
quality of life and to prevent recurrence of paradoxical 
embolism. Assessment of patient eligibility can also be 
done more easily using available scoring sytems. With 
the advances in medicine, closure of patent foramen 
ovale can be done safely through percutaneous access. 
Percutaneous access can help patent foramen ovale 
Closure to be more widely available across centers.
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